SS Innovations International, Inc. (SSII) - Q3 2025 10-Q Summary
Business Context and Reporting Period
SS Innovations International, Inc. (SSII) designs, manufactures, and markets the "SSi Mantra" surgical robotic system and related instruments. The company operates primarily from its manufacturing facility in India and recently uplisted to the Nasdaq Stock Market in April 2025. This report covers the quarterly period ended September 30, 2025, and the nine months ended September 30, 2025.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Total Revenue | $12.83 million | $4.39 million | $27.95 million | $12.53 million |
| Gross Profit | $6.16 million | $2.32 million | $13.17 million | $4.48 million |
| Gross Margin | 48.1% | 52.8% | 47.1% | 35.8% |
| Net Loss | $(3.72) million | $(3.25) million | $(9.66) million | $(17.23) million |
| Operating Cash Flow | N/A | N/A | $(17.02) million | $(6.24) million |
| Cash & Equivalents | $5.68 million | $0.47 million | $5.68 million | $0.47 million |
| Restricted Cash | $6.36 million | $6.16 million | $6.36 million | $6.16 million |
| Total Debt (Bank Overdraft) | $10.07 million | $7.99 million | $10.07 million | $7.99 million |
Note: Stock compensation expense was $2.10 million for Q3 2025 and $6.10 million for YTD 2025.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 192% in Q3 2025 compared to Q3 2024, driven by the sale of 28 surgical robotic systems in the quarter (55 systems YTD). System sales accounted for the majority of revenue.
- Profitability: While the Net Loss increased slightly in Q3 2025 compared to Q3 2024, the YTD Net Loss decreased significantly by 44% ($7.57 million improvement) due to higher gross profits and a reduction in stock compensation expenses.
- Income Tax: The company recorded an income tax expense of $1.85 million for Q3 2025 and $2.20 million YTD, compared to nil in the prior year periods. This marks the first recognition of current tax expense in Indian operations due to taxable profits.
- Balance Sheet: Total assets grew from $42.4 million to $69.6 million, primarily due to increases in inventory ($20.0 million), accounts receivable ($13.8 million total), and cash positions.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern for the next 12 months. The company relies on related-party financing and has not yet established consistent operational cash flows to meet fixed costs.
- Capital Resources: The company successfully raised $28 million in convertible notes from a principal stockholder in January 2025, which were subsequently converted into common stock. There are no committed sources of future funding.
- Internal Controls: The company disclosed material weaknesses in internal controls over financial reporting, including inadequate design of controls for U.S. GAAP application and lack of segregation of duties. Remediation efforts are underway, including the implementation of a cloud-based ERP system.
- Unusual Items: A significant portion of the YTD stock compensation expense reduction ($5.9 million) was due to the reversal of expenses related to resigned employees.
Investor Verification Checklist
- Going Concern Status: Verify the company's ability to secure additional funding beyond related-party support to sustain operations for the next 12 months.
- Internal Control Remediation: Monitor progress on the remediation of material weaknesses in internal controls and the implementation of the new ERP system.
- Revenue Recognition: Review the breakdown of deferred revenue ($8.79 million) and the timing of revenue recognition for deferred payment arrangements.
- Related Party Transactions: Assess the dependency on related parties for financing (convertible notes) and the terms of future capital raises.
- Inventory Levels: Analyze the significant increase in inventory ($20.0 million) relative to sales velocity and potential obsolescence risks.